Del i serien Novel approaches to overcome cancer resistance to conventional therapies

PROTACs Overcome Resistance to Cancer Therapies

Häftad, Engelska, 2027

2 289 kr

Kommande

PROTACs Overcome Resistance to Cancer Therapies explores the transformative potential of proteolysis targeting chimeras (PROTACs) in addressing one of oncology’s greatest challenges: drug resistance. Edited by Dr. Daohong Zhou, this volume brings together leading experts to present the latest advances in targeted protein degradation for cancer treatment. The book covers foundational principles of PROTAC design, mechanisms of action, and their advantages over traditional small molecule inhibitors. It delves into strategies for targeting undruggable proteins, overcoming resistance in various cancer types, and mitigating emerging resistance to PROTACs. Case studies include BCL-xL, KRAS, STAT3, and EGFR-targeting PROTACs, with insights into clinical translation and precision medicine. This resource equips cancer researchers, oncologists, and pharmaceutical scientists with practical guidance and cutting-edge knowledge. It serves as both a reference and a roadmap for developing next-generation therapeutics, making it essential for those advancing cancer drug discovery and translational medicine.

Explains the foundational principles of targeted protein degradation and highlights how PROTACs surpass traditional small molecule inhibitors in efficacy and specificity.
Showcases diverse applications of PROTACs in targeting undruggable proteins and resistant mutations, supported by case studies and translational research insights
Equips researchers with methodologies for PROTAC design, optimization, and evaluation, while addressing emerging resistance mechanisms and clinical implications

Produktinformation

Utgivningsdatum2027-01-01
Mått191 x 235 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
SerieNovel approaches to overcome cancer resistance to conventional therapies
Antal sidor330
FörlagElsevier Science
ISBN9780443444265

Tillhör följande kategorier

Biologi inom Naturvetenskap och teknik

Dr. Daohong Zhou is a professor at the University of Texas Health San Antonio and holds the Joe R. and Terry Lozano Long Distinguished Chair of Developmental Therapeutics. He co-directs the Center of Innovative Drug Discovery and serves as Associate Director for Drug Development at the Mays Cancer Center. With over 200 publications, Dr. Zhou is a pioneer in senolytic and cancer therapeutics research. He discovered ABT263, a dual Bcl-2/Bcl-xL inhibitor, and developed several PROTACs targeting BCL-xL and other proteins. His work led to the FDA approval of DT2216 in phase I trials and the founding of Unity Biotechnology and Dialectic Therapeutics.

1. General Introduction of PROTACs as Novel Therapeutics for Cancer2. Methodologies to Prepare, Optimize, and Evaluate PROTACs3. PROTACs and Precision Medicine4. Using PROTACs to Target BCL-2 Family Antiapoptotic Proteins to Overcome Cancer Drug Resistance5. Estrogen Receptor (ER) PROTAC Vepdegestrant (ARV-471) for Advanced Breast Cancer Treatment6. Using PROTACs to Target BTK Mutants to Overcome Drug Resistance7. STAT3 PROTACs8. KRAS PROTACs9. Mutant-Selective Allosteric EGFR Degraders10. MDM2 PROTACs to Overcome Drug Resistance in p53-Mutated Cancer11. ABCB1 and PROTAC Resistance12. Mutations of the Genes in the Ubiquitin Proteasome System and PROTAC Resistance13. General Conclusions, Challenges and Future Perspectives